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A B S T R A C T
Purpose: Better knowledge of risk factors for women with epilepsy giving birth.
Method: Investigating all studies reporting complications in pregnancy and deliveries in women with
epilepsy during the last 15 years.
Results: Studies have observed that women with epilepsy have a higher risk of preeclampsia, gestational
hypertension, bleeding in pregnancy, caesarean delivery (CD), excessive bleeding postpartum, preterm
birth, and small for gestational age. It has been unclear whether the increased risk of complications is due
to the epilepsy per se, the use of antiepileptic drugs (AED), or the combination of both factors. Recent
studies strongly indicate an association between AED use, and complications in pregnancy and labour.
Conclusion: Newer drugs commonly used in treatment of epilepsy are associated with an increased risk
of pregnancy complications, as well as complication during labour and delivery.
 2015 Published by Elsevier Ltd on behalf of British Epilepsy Association.
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Epilepsy is a common neurological disease with a lifetime
prevalence of 0.6% in developed countries and 1.5% in developing
countries [24]. The prevalence of epilepsy in epidemiological
studies is estimated to 0.3–0.7% in pregnant women [8,15]. Im-
proved diagnosis and therapy of epilepsy have allowed more
women with epilepsy to conceive [18]. The vast majority of these
women will have uneventful pregnancies. However, epidemiologi-
cal studies enrol the entire spectrum of the disease, and women
being pregnant may represent the healthy proportion of the
population with well-controlled epilepsy [8,29,35].
Epilepsy is one of the most common causes of seizures during
pregnancy. It may require continuous drug treatment, also during
pregnancy, to avoid seizures. This treatment is potentially
teratogenic and women with epilepsy will have to balance the
risk of serious seizures against the risk of teratogenic exposure to
the foetus [13,33]. It has also been demonstrated an increased risks
of pregnancy complications in women using AEDs [8]. It has been
unclear whether the risk of complications is due to epilepsy per se,
the use of AEDs or the combination of these factors.
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Most women with epilepsy have uncomplicated pregnancies
and normal deliveries [8,33]. However, pregnancies of women
with epilepsy represent a greater risk of complications, and seizure
frequency may alter [20,30]. Until recently, very little was known
about the association between AED and spontaneous abortion in
women with epilepsy. A epidemiological study from Denmark
including 4700 pregnancies with AED did not observe any
increased risk of abortion in women with epilepsy [4]. In this
study 34% were using lamotrigine.
In a study from 1973, Bjerkedal and Bahna used data from the
Medical Birth Registry of Norway to study women with epilepsy
delivering during 1967–1968. They demonstrated an increased
risk of bleeding in pregnancy, an increased risk of preeclampsia,
induction of labour, low birth weight <2500 g and a higher
mortality rate in the neonatal period. There was no information
about medication in this study [5]. In 1985, Yerby and his
collaborators studied birth certiﬁcates from Washington State
during 1980–1981. They identiﬁed 204 women with epilepsy
and used a random of 612 women without epilepsy as controls.
They observed an increased risk of previous foetal loss [Odds
ratio (OR): 2.66 (95% conﬁdence interval (CI): 1.01–6.98)],
preeclampsia [OR: 2.45 (1.17–5.51)], low Apgar score <7 after
5 min [OR: 3.74 (1.57–8.88)], and low birth weight <2500 g [OR:
2.79 (1.35–5.74)] in women with epilepsy [37]. They also
demonstrated an increased risk of induction for labour [OR: 4.29
(1.77–10.39)] and an increased risk of CD [OR: 1.93 (1.31–2.83)].
However, in a Finnish study, they were not able to demonstrate
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compared with 152 women without epilepsy [17]. A lot of studies
followed, none were able to demonstrate any pregnancy complica-
tions in women with epilepsy [12,19,21,36]. In 2004, a Canadian
group was looking at the obstetrical and neonatal outcome in all
women with epilepsy giving birth at a tertiary referral hospital. They
identiﬁed 414 births with epilepsy and 81,759 births without
epilepsy. They observed an increased risk of hypertension, induction
of labour and CD in women without epilepsy. They could not observe
any signiﬁcant difference in the rate of outcome when women with
AED use were compared with women without AED use. In 2009, a
study from Norway using data from the Medical Birth Registry of
Norway, reported an increased risk of pregnancy complications
[8]. Our national register-based cohort study comprised a total
national population collected 1999–2006, and included 942 women
with epilepsy using AED during pregnancy. This unselected cohort
was compared with the full national cohort of women without a
history ofepilepsy. We observed a low, but deﬁnitely increased riskof
gestational hypertension, OR: 1.5 (1.0–2.2). Primiparous women had
the highest risk OR: 2.4 (1.0–5.4). Women with epilepsy using AED
also had an increased risk of mild preeclampsia, OR: 1.7 (1.2–2.3).
This ﬁnding was supported by our hospital-based study where
women with epilepsy and AED use was examined in more detail
[7]. In this study a sample of 205 consecutive deliveries at Haukeland
University Hospital with a conﬁrmed diagnosis of maternal epilepsy
in the Medical Birth registry of Norway (MBRN) in the period 1st
January 1999 to 31st December 2006, were identiﬁed. A control
group of 205 women with the same age and parity, delivering at the
same date were used. We observed that women with epilepsy and
AED use had an increased risk of severe preeclampsia and early
vaginal bleeding, OR: 5.0 (1.3–19.9) and OR: 6.4 (2.7–15.2),
respectively. These data were adjusted for maternal education,
smoking, body mass index, medical conditions and diabetes. The
increased risk of preeclampsia was related to use of lamotrigine
monotherapy in pregnancy, OR: 7.5 (1.4–39.0). This effect of
lamotrigine in pregnancy is similar to what has previously been
reported for carbamazepine [35]. We also observed that both active
epilepsy and no active epilepsy had an increased risk of severe
preeclampsia, OR: 4.1 (1.0–16.8) and OR: 4.2 (1.0–17.4), respectively.
This increased risk was only observed in AED users.
Bleeding in pregnancy was also related to both lamotrigine
monotherapy, OR: 6.2 (2.0–19.3), and also to polytherapy
including lamotrigine, OR: 8.6 (2.8–26.3).
The higher risk of hypertensive disorders in women with
epilepsy is also observed in a study from India. They compared
718 women with epilepsy with 18,272 women without epilepsy
during 1998–2005. Women with epilepsy had an increased risk of
hypertension, OR: 1.42 (1.05–1.91) and preeclampsia OR: 2.05
(1.37–3.06) and there were no differences between AED users and
no AED users. In this study, 40% were using carbamazepine and
2.5% were using lamotrigine [32].
Preterm delivery has been observed in women with epilepsy
not using AEDs [21], but not in all studies [19,23]. In our population
based study, we observed an increased risk of preterm birth before
34 weeks of gestation in women with epilepsy using AEDs, OR: 1.6
(1.2–2.1) [8]. In our hospital-based study, both epilepsy with and
without AED use had an increased risk of preterm birth before
32 weeks of gestation [7]. The risk persisted after we adjusted for
maternal age, and education, smoking, previous CD, preeclampsia,
vaginal bleeding, medical conditions, and diabetes.
Children of women with epilepsy may be at increased risk of
intrauterine growth restriction [9]. Causative factors could be the
epilepsy, exposure to AEDs, seizures, genetic aspects as well as any
underlying condition and environmental factors. A study from
Sweden estimated the effect on head growth of exposure in utero to
the new AEDs lamotrigine and gabapentin, and the old AEDsphenytoin, clonazepam, carbamazepine and valproate [2]. Carba-
mazepine had the strongest effect, whereas phenytoin, clonaze-
pam, lamotrigine and gabapentin had no such effects. This ﬁnding
is also demonstrated in a recent study from the Medical Birth
Registry of Norway (MBRN) [34], and in a study from Finland [3].
The incidence of CD has been increasing worldwide. The
incidence is also increasing for women with epilepsy. CD frequency
varies between cohorts of women with epilepsy, both increased
and no increased CD risk being reported [19,28,29,32,36]. Our
national cohort study demonstrated an increased incidence of CD
for women with epilepsy, OR: 1.4 (1.3–1.6) [6]. This was conﬁrmed
in our hospital study where women with epilepsy and AED use had
a doubled risk for CD, OR: 2.3 (1.2–4.3) after adjusting for maternal
education, smoking, body mass index, medical conditions and
diabetes. However, when adding preterm birth in the regression
analysis, the women with epilepsy had no longer any signiﬁcantly
increased rate of overall CD, OR: 1.7 (1.0–3.0) (p = 0.065) [7]. The
higher incidence of CD among women with epilepsy most probably
has a multi-factorial background. It can be mediated by the
increase in foetal growth restriction, hypertensive disorders of
pregnancy, and seizures in pregnancy. Most chronic medical
disorders increase the likelihood of CD [22]. Epilepsy represents a
signiﬁcant disorder, but is not an indication for CD unless a seizure
occurs during the second stage of labour and the patient cannot
cooperate during a vaginal delivery because of sedation [11]. An-
other reason for the difference observed may be the high rates of
CD in the healthy, obstetrical population in most other countries, in
contrast to the low CD rate in Norway of 14.3% in the years studied
[23,29,32]. Better knowledge of risk assessment in women with
epilepsy giving birth, will probably decrease the rates of CD in
these women. The guidelines of the National Institute for Health
and Clinical Excellence in United Kingdom, the American Academy
of Neurology Practice Parameter update and the Italian Consensus
Conference recommend vaginal delivery in women with epilepsy,
with the exception of women with frequent seizures [1,14,25]. On-
ly a few studies have explored complications for women with
epilepsy during labour and delivery. Induced labour is more
frequent in women with epilepsy, even though epilepsy is not an
indication for induction [19,29]. This is also in accordance with our
two studies [6,7]. In our national cohort study, we observed an
increased risk of induction for women with epilepsy and AED use,
OR: 1.6 (1.4–1.9) [6], similar to our hospital based study, OR: 2.3
(1.2–3.4) [7]. In the last study, we adjusted for maternal age,
education, smoking, BMI 30, diabetes and medical conditions.
According to guidelines in England and Norway, induction of
labour in women with epilepsy should be evaluated on an
individual basis [25,31]. Deliveries with forceps and vacuum do not
occur with increased frequency in women with epilepsy
[6,13,29]. This may be due to the high rates of CD, but most
probably also reﬂects few complications during labour.
Postpartum haemorrhage has been deﬁned as bleeding more
than 500 ml during labour and after delivery [10]. We observed
that women with epilepsy and AED use had an increased risk of
postpartum bleeding, OR: 1.5 (1.3–1.8), operative vaginal deliver-
ies having the highest risk [6]. This increased risk of bleeding was
associated with use of valproate and lamotrigine during pregnan-
cy. Most previous studies have not found any association between
epilepsy and postpartum haemorrhage [16,19,26]. The differences
may be due to patient selection and small sample sizes in the
hospital based studies while our study comprises a whole national
cohort. Our study is supported by a study from Sweden where an
increased risk of postpartum bleeding after vaginal deliveries in
women using AEDs was found [28]. Also in our hospital based
study, we observed an increased risk of postpartum haemorrhage
in women using valproate. We also observed that women with
epilepsy and AED use had an increased risk of uterine atony, which
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Induction and CD also represent risk factors for postpartum
haemorrhage, but these factors were not observed to inﬂuence
bleeding in this study.
Careful management is essential to minimize the risks. Women
with epilepsy should have a preconceptional dialogue with focus
on the importance of a planned pregnancy with optimizing AED
use, folate supplementation, the teratogenicity of AEDs versus the
risks of seizures, and the risk of obstetric complications [27].
3. Conclusion
Although most women with epilepsy have uneventful preg-
nancies and healthy babies, they face certain challenges. Women
with active epilepsy will usually require AED therapy during
pregnancy in order to avoid adverse effects of uncontrolled
seizures on themselves and their foetus. However, AEDs carry a
potential risk of developmental toxicity as well as long-term
effects to the foetus.
Women with epilepsy and AED use has an increased risk of
preeclampsia, bleeding in pregnancy and preterm birth. These risks
seem to be associated with the use of lamotrigine and also of
carbamazepine. There is a higher frequency of low birth weight
(<2500 g) and small head circumference at birth for children of
mothers with epilepsy. These risks are associated with use of
carbamazepine.
There is a tendency for a change in medication of young women
with epilepsy from valproate to carbamazepine and lamotrigine.
However, the use of these medications is linked to an increased risk
of maternal complications. Women using all types of AEDs should
therefore be monitored closely during pregnancy.
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